IGNIS: Transcriptomic Analysis for Drug Repurposing Across the Gut-Brain Axis
ISEF · 2026 Computational Biology and Bioinformatics
Overview
Neurodegenerative and intestinal diseases impact millions of people worldwide. Considering their gut-brain axis connection, IGNIS tested the hypothesis of a shared protein target for drug repurposing among ten of these illnesses. Using 17 gene expression profiling datasets (1,346 patients and 1,362 controls in total), more than 100 common differentially expressed genes were identified in subsets of up to seven diseases. Based on these genes, a shared target was selected through regulatory and protein-protein interaction (PPI) networks and functional enrichment. Alongside three reference inhibitors, 1,541 compounds approved by the FDA and/or EMA were subjected to docking, in which the top-ranked compounds advanced for a refined docking and a 50 ns molecular dynamics simulation. PPI networks revealed 28 central hub genes, five extensive clusters, and 14 key genes. There were 19 transcriptional factors and 17 miRNAs recognized as potential regulatory biomarkers for seven diseases, and functional enrichment highlighted inflammatory metabolic pathways. STAT3 was identified as a shared target of five diseases, and 24 samples outperformed STAT3 controls in average binding energy by up to 13%. In refined docking (exhaustiveness = 32), five samples matched or exceeded the performance of two controls in ligand efficiency, with an improvement of up to 9%. The 50 ns molecular dynamics simulations highlighted Nilotinib-STAT3 complex's stability, with a 31.43% lower peak than the control TTI-101 in RMSD. With reproducible procedures, this study provided evidence that Nilotinib, Avapritinib, Ubrogepant, Atogepant, and Zafirlukast are prioritized candidates for further drug repurposing validation aimed at new therapies in the gut-brain axis.
Competition history
- ISEF 2026
Resources
Related projects
ISEF · 2024
Identification of Novel Target Genes and ML-Based Drug Repurposing and Discovery for Alzheimer’s Disease in the Presence of Metabolic Comorbidities
ISEF · 2026
AI-Driven Graph Neural Networks for Dual-Target AChE and BACE1 Drug Repurposing in Alzheimer’s Disease
ISEF · 2021
The Identification and Validation of Novel Targets and Pathways of Alzheimer's Disease Through Integrated System Approaches
ISEF · 2026
Drug Discovery of Novel Oxindole Derivatives as Multitarget Modulators in Alzheimer's Disease
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair